HDT Bio logo

HDT Bio

hdt.bio

HDT Bio is a clinical-stage biopharmaceutical company developing vaccines and immunotherapies for cancer and infectious diseases using its proprietary LION™ technology. Its products are designed to harness the immune system to prevent and treat disease.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2018
Type
Corporation Seattle business license
Employees
51
Registered name
HDT Bio Corp Seattle business license
Stage
Clinical-stage
Founders
Andre Lieber

Is this your organization? Claim it

Seattle Biotech Myosana Raises $5M to Develop Advanced Gene Therapy for Duchenne Muscular Dystrophy

Myosana Therapeutics, a Seattle biotech co-founded by University of Washington researchers, raised $5 million to advance a novel gene therapy candidate targeting Duchenne muscular dystrophy (DMD). The company aims to develop a gene delivery platform that can handle larger DNA segments compared to current standard methods, potentially improving treatment options against DMD.

Seattle Startup HDT Bio Secures $1.8M U.S. Army Grant to Develop Broad-Spectrum Antiviral Nasal Spray by 2025

Seattle startup HDT Bio received a nearly $1.8 million U.S. Army grant to develop a nasal spray using proprietary RNA technology that targets a broad range of respiratory viruses, with clinical trials expected to begin in 2025. The spray aims to prevent virus replication and transmission and could be used by both military personnel and civilians.

See all 7 stories, episodes and videos about HDT Bio.

People

  • André Lieber Scientific Co-Founder
  • Steven Reed Co-Founder & CEO

Online